What NovaBridge Biosciences's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 3 | 7 |
| Total trades | 9 | 17 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 17 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Woo Ian Ying | Director | Oct 15 | Exercise / conversion · M | +13,271 | — | — | 13,271 |
| Dennis Phillip Andrew | Chief Medical Officer | Sep 18 | Open-market sale · S | −8,209 | $0.71 | −$5.83K | 173,427 |
| Dennis Phillip Andrew | Chief Medical Officer | Sep 17 | Exercise / conversion · M | +23,695 | — | — | 181,636 |
| Cao Sean Wuxiong | Chief Bus. Development Officer | Sep 09 | Open-market sale · S | −107,978 | $0.74 | −$79.9K | 266,467 |
| Cao Sean Wuxiong | Chief Bus. Development Officer | Sep 03 | Exercise / conversion · M | +104,236 | — | — | 374,445 |
| Cao Sean Wuxiong | Chief Bus. Development Officer | Sep 03 | Exercise / conversion · M | +235,136 | — | — | 270,209 |
| Xu Cong Claire | EVP, Clinical Development | Aug 31 | Open-market sale · S | −3,282 | $0.79 | −$2.59K | 304,201 |
| Xu Cong Claire | EVP, Clinical Development | Aug 30 | Exercise / conversion · M | +9,382 | — | — | 307,483 |
| Lenz Robert A. | Director | Aug 22 | Exercise / conversion · M | +17,218 | — | — | 17,218 |
| Xu Cong Claire | SVP, Clinical Development | Jul 06 | Open-market sale · S | −4,485 | $0.89 | −$3.99K | 298,101 |
| Xu Cong Claire | SVP, Clinical Development | Jul 04 | Exercise / conversion · M | +12,432 | — | — | 302,586 |
| Dennis Phillip Andrew | Chief Medical Officer | Jun 18 | Open-market sale · S | −8,494 | $0.66 | −$5.61K | 157,941 |
| Dennis Phillip Andrew | Chief Medical Officer | Jun 17 | Exercise / conversion · M | +23,695 | — | — | 166,435 |
| Xu Cong Claire | SVP, Clinical Development | Jun 01 | Open-market sale · S | −3,494 | $3.94 | −$13.8K | 290,154 |
| Xu Cong Claire | SVP, Clinical Development | May 30 | Exercise / conversion · M | +9,382 | — | — | 293,648 |
| Cao Sean Wuxiong | See Remarks | May 14 | Open-market sale · S | −21,399 | $1.99 | −$42.6K | 35,073 |
| Hagler Mark Arnold | See Remarks | Apr 24 | Open-market buy · P | +230,000 | $2.51 | +$577K | 230,000 |
Loading...
